Last update 21 Nov 2024

Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Natural Killer Cell Therapies

Synonyms

Natural Killer Mixture(The People's Hospital of Dazu, Chongqing)

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Colorectal Cancer

Inactive Indication-

Originator Organization

The People's Hospital of Dazu, Chongqing

Active Organization

The People's Hospital of Dazu, Chongqing

Inactive Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

Clinical Trials associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

ChiCTR2300075861 / RecruitingIIT

Efficacy and safety of Natural Killer cells injection combined with XELOX chemotherapy for postoperative colorectal cancer patients

Start Date01 Mar 2024

Sponsor / Collaborator-

100 Clinical Results associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

100 Translational Medicine associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

100 Patents (Medical) associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

Literatures (Medical) associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

01 Nov 2024·Cell Proliferation

Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity

Article

Author: Wang, Jinyong ; Liu, Yanhong ; Wang, Zhiqian ; Huang, Dehao ; Qian, Wenbin ; Liu, Lijuan ; Zhu, Xiaofan ; Li, Jianhuan ; Hu, Fangxiao ; Wang, Tongjie ; Zhang, Leqiang ; Wang, Yao ; Xia, Chengxiang ; Qi, Hanmeng ; Zhang, Fan ; Zhang, Mengyun ; Zhu, Yanping ; Zhao, Yaoqin

AbstractChimeric antigen receptor‐natural killer (CAR‐NK) cell therapy is emerging as a promising cancer treatment, with notable safety and source diversity benefits over CAR‐T cells. This study focused on optimizing CAR constructs for NK cells to maximize their therapeutic potential. We designed seven CD19 CAR constructs and expressed them in NK cells using a retroviral system, assessing their tumour‐killing efficacy and persistence. Results showed all constructs enhanced tumour‐killing and prolonged survival in tumour‐bearing mice. In particular, CAR1 (CD8 TMD‐CD3ζ SD)‐NK cells showed superior efficacy in treating tumour‐bearing animals and exhibited enhanced persistence when combined with OX40 co‐stimulatory domain. Of note, CAR1‐NK cells were most effective at lower effector‐to‐target ratios, while CAR4 (CD8 TMD‐OX40 CD‐ FcεRIγ SD) compromised NK cell expansion ability. Superior survival rates were noted in mice treated with CAR1‐, CAR2 (CD8 TMD‐ FcεRIγ SD)‐, CAR3 (CD8 TMD‐OX40 CD‐ CD3ζ SD)‐ and CAR4‐NK cells over those treated with CAR5 (CD28 TMD‐ FcεRIγ SD)‐, CAR6 (CD8 TMD‐4‐1BB CD‐CD3ζ 1‐ITAM SD)‐ and CAR7 (CD8 TMD‐OX40 CD‐CD3ζ 1‐ITAM SD)‐NK cells, with CAR5‐NK cells showing the weakest anti‐tumour activity. Increased expression of exhaustion markers, especially in CAR7‐NK cells, suggests that combining CAR‐NK cells with immune checkpoint inhibitors might improve anti‐tumour outcomes. These findings provide crucial insights for developing CAR‐NK cell products for clinical applications.

01 Feb 2023·Trends in Cancer

The emerging field of oncolytic virus-based cancer immunotherapy

Review

Author: Yu, Jianhua ; Li, Zhenlong ; Ma, Rui ; Caligiuri, Michael A ; Chiocca, E Antonio

Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate antitumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment. However, some limitations, such as limited penetration of OVs into tumors, short persistence, and the host antiviral immune response, are impeding the broad translation of oncolytic virotherapy into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, may provide powerful therapeutic platforms in the clinic.

Frontiers in ImmunologyQ2 · MEDICINE

Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model

Q2 · MEDICINE

ArticleOA

Author: Gangadaran, Prakash ; Lee, Jaetae ; Baek, Se Hwan ; Jeong, Shin Young ; Ahn, Byeong-Cheol ; Zhu, Liya ; Kalimuthu, Senthilkumar ; Li, Xiu Juan ; Lee, Sang-Woo ; Lee, Ho Won ; Oh, Ji Min

OBJECTIVENatural killer (NK) cells represent the third largest population of lymphocytes, and they play an important role in immune surveillance against tumors. The lungs are a common metastatic site for anaplastic thyroid cancer (ATC), and metastasis is one of the most frequent causes of mortality in this type of cancer. In the current study, we evaluated the effects of NK cell-based immunotherapy for pulmonary metastasis of ATC and determined how it affects the effector molecules of NK cells.METHODSHuman NK cells (NK-92MI) were retrovirally transduced to express the effluc gene. Human ATC cells (CAL-62) were transduced with the effluc and Rluc genes. The cytotoxicity of NK cells against CAL-62 cells was assessed using the CytoTox 96^® Non-Radioactive Cytotoxicity Assay system. Pulmonary metastases of ATC were developed by i.v. injection of CAL-62, and metastasis growth was monitored using bioluminescence imaging (BLI). To treat the metastases, five million NK-92MI cells were injected twice into the caudal vein of nude mice. To assess the targetability of NK cells to ATC tumors, NK-92MI cells expressing the effluc gene (NK/F) were administered through the tail vein of nude mice with a pulmonary metastasis or tumor xenograft. BLI was subsequently performed at 1, 3, 24, and 48 h.RESULTSNK/F and CAL-62 cells expressing the effluc or Rluc gene (CAL-62/F, CAL-62/R) were successfully established. Expression of the effluc and Rluc genes in NK/F, CAL-62/F, and CAL-62/R cells was verified by RT-polymerase chain reaction, western blotting, and luciferase assay. After coculture of NK-92MI and CAL-62/F cells for 24 h, the BLI signal intensity of CAL-62/F cells proportionally decreased with the number of cocultured NK cells. An ATC pulmonary metastasis mouse model was successfully generated, and NK cells significantly inhibited the growth of the metastasis (p < 0.01). The NK/F cells exhibited targetability to the pulmonary metastasis and tumor xenograft in the mouse model.CONCLUSIONThe results of present study suggest that NK cells are able to target ATC tumors and that NK cell-based immunotherapy may serve as an effective therapeutic approach for pulmonary metastases of ATC.

100 Deals associated with Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Natural Killer (NK) Cells(The People's Hospital of Dazu, Chongqing)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation